Last Updated on July 28, 2021 by HepFree NYC
Related Articles
-
Hep B & C in NYC: 2016 Annual Report of Surveillance & Activities
This report presents an overview of the New York City Health Department’s 2015 surveillance and research data on hepatitis B and C in NYC, as well as the Health Department’s programmatic activities to address these epidemics.
-
NYC Health Department Announces Strategic Plan to Combat Hepatitis C
The NYC Health Department today released the City's first-ever plan for reducing illness and death from the hepatitis C virus (HCV), a disease that now accounts for more annual deaths nationwide than HIV/AIDS
-
Press Release | 2016 World Hepatitis Day (Hep Free NYC)
World Hepatitis Day provides a platform for people to speak out, be engaged and take action to ensure global commitments are met and viral hepatitis is eliminated by 2030.
-
Team HBV NYC
There are numerous opportunities available for students to assist NYC Hepatitis B Coalition member organizations through internships and volunteer projects.
-
FDA Approves Daklinza/Sovaldi to Treat Hep C Genotype 1
FDA Expands Daklinza/Sovaldi Approval to Include Treatment of Hep C Genotype 1
-
Article 2015 | Recommendations for Management of Hep C among People Who Inject Drugs
In high income countries, the majority of new and existing hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). In many low and middle income countries large HCV epidemics have also emerged among PWID populations.
-
FDA Approves Viekira Pak to Treat Hep C
FDA Approves Viekira Pak to Treat Hep C A new hepatitis C medication, Viekira Pak, was approved today by the U.S. Food and Drug Administration (FDA). AbbVie, who markets the drug, has not immediately released the price of the new all-oral Hep C medication which will now rival Ha...
-
Hospitals | Apply for Hep B Universal Birth Dose Honor Roll
The Hep B Vaccine Birth Dose Honor Roll: recognizes hospitals and birthing centers with excellent birth dose coverage.
